Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional

Federal funding opportunity FOR-FD-24-005 from Food and Drug Administration.

View forecast on Grants.gov →Forecasted — not yet open · no update since November 30, 2023

Program funding history

Synopsis

Who can apply

• Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
• City or township governments
• Others (see text field entitled "Additional Information on Eligibility" for clarification)
• Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
• Special district governments
• Small businesses
• Independent school districts
• Native American tribal governments (Federally recognized)
• For profit organizations other than small businesses
• Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
• Native American tribal organizations (other than Federally recognized tribal governments)
• Private institutions of higher education
• State governments
• Public housing authorities/Indian housing authorities
• Public and State controlled institutions of higher education
• County governments

Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The FDA will not accept duplicate or highly overlapping applications under review at the same time per 2.3.7.4 Submission of Resubmission Application. This means that the NIH or FDA will not accept:•A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.•A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.•An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

How to apply

Similar grants

• Utilizing Real-World Data and Algorithmic Analyses to Assess Post-Market Clinical Outcomes in Patients Switching Amongst Therapeutically Equivalent Complex Generic Drug Products and Reference Listed Drugs (U01) Clinical Trial Not Allowed
  FOR-FD-24-003 · Food and Drug Administration
• Identification of Drug-related and Formulation-Related Factors that Result in Alcohol Dose Dumping of Modified Release Oral Drug Products (U01) Clinical Trial Not Allowed
  FOR-FD-24-006 · Food and Drug Administration
• Developing PBPK Model-Based Mechanistic IVIVCs for Long Acting Injectable Suspensions and Implants (U01) Clinical Trial Optional
  FOR-FD-24-002 · Food and Drug Administration
• Integrating Machine Learning with Computational Fluid Dynamics Models of Orally Inhaled Drug Products (U01) Clinical Trials Not Allowed
  FOR-FD-24-001 · Food and Drug Administration
• Synthesis and Biological Activity Assessment of Different Diastereomers in siRNA Drug LEQVIO (Inclisiran) (U01) Clinical Trial Not Allowed
  FOR-FD-24-007 · Food and Drug Administration
• Flexible Funding Model-Infrastructure Development and Maintenance for State Manufactured Food Regulatory Programs (U2F) Clinical Trials Not Allowed
  FOR-FD-24-009 · Food and Drug Administration